Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Primary myelofibrosis (PMF) involves bone marrow fibrosis, myeloproliferation, and extramedullary hematopoiesis, often driven by atypical megakaryocytes releasing cytokines like TGF-β.
• Current treatments like ruxolitinib offer symptomatic relief but do not address the underlying fibrosis or mutant allele burden.

Purpose of the Study:

• To investigate Aurora kinase A (AURKA) as a novel therapeutic target for primary myelofibrosis.
• To evaluate the efficacy of AURKA inhibition in preclinical models of PMF.

Main Methods:

• Pharmacologic inhibition of AURKA using the selective inhibitor MLN8237.
• Genetic studies involving heterozygous deletion of Aurka in mouse models of PMF.
• Assessment of megakaryocyte polyploidization, differentiation, and antifibrotic/antitumor activity in vivo.

Main Results:

• MLN8237 treatment promoted megakaryocyte polyploidization and differentiation in PMF models.
• Selective AURKA inhibition demonstrated potent antifibrotic and antitumor effects in vivo.
• Heterozygous deletion of Aurka ameliorated key features of PMF, including bone marrow fibrosis.

Conclusions:

• Megakaryocytes play a significant role in driving fibrosis in primary myelofibrosis.
• Targeting AURKA with inhibitors presents a promising therapeutic strategy for PMF, potentially addressing both fibrosis and disease progression.